No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom.

TitleNo Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom.
Publication TypeJournal Article
Year of Publication2016
AuthorsWhite E, Smit E, Churchill D, Collins S, Booth C, Tostevin A, Sabin C, Pillay D and Dunn D
Corporate AuthorsUK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study
JournalJ Infect Dis
Volume214
Issue9
Pagination1302-1308
Date Published2016 Nov 01
ISSN1537-6613
KeywordsAdult, Anti-HIV Agents, Cohort Studies, Drug Resistance, Viral, Female, HIV Infections, HIV-1, Humans, Male, Middle Aged, Mutation, Reverse Transcriptase Inhibitors, Tenofovir, Treatment Failure, United Kingdom
Abstract

Concern has been expressed that tenofovir-containing regimens may have reduced effectiveness in the treatment of human immunodeficiency virus type 1 (HIV-1) subtype C infections because of a propensity for these viruses to develop a key tenofovir-associated resistance mutation. We evaluated whether subtype influenced rates of virological failure in a cohort of 8746 patients from the United Kingdom who received a standard tenofovir-containing first-line regimen and were followed for a median of 3.3 years. In unadjusted analyses, the rate of failure was approximately 2-fold higher among patients infected with subtype C virus as compared to those with subtype B virus (hazard ratio [HR], 1.86; 95% confidence interval [CI], 1.50-2.31; P < .001). However, the increased risk was greatly attenuated in analyses adjusting for demographic and clinical factors (adjusted HR, 1.14; 95% CI, .83-1.58; P = .41). There were no differences between subtypes C and subtypes non-B and non-C in either univariate or multivariate analysis. These observations imply there is no intrinsic effect of viral subtype on the efficacy of tenofovir-containing regimens.

DOI10.1093/infdis/jiw213
Alternate JournalJ. Infect. Dis.
PubMed ID27732929
PubMed Central IDPMC5079361
Grant ListMC_UU_12023/15 / / Medical Research Council / United Kingdom
MR/M004236/1 / / Medical Research Council / United Kingdom